Cover Image
市場調查報告書

胃癌治療藥的全球市場 2016-2020年

Global Gastric Cancer Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 347450
出版日期 內容資訊 英文 99 Pages
訂單完成後即時交付
價格
Back to Top
胃癌治療藥的全球市場 2016-2020年 Global Gastric Cancer Drugs Market 2016-2020
出版日期: 2015年12月16日 內容資訊: 英文 99 Pages
簡介

全球胃癌治療藥市場規模,在預測期間以約8%的年複合成長率急速成長。市場上巨大的未滿足需求的存在,預計在預測期間該市場健全成長。還有近幾年的生活方式的變化造成胃癌盛行率的上升,預計胃癌治療藥市場擴大。

本報告提供全球胃癌治療藥市場相關調查分析、市場規模與成長率的預測、主要的促進成長要素、市場影響成長趨勢、市場成長的相關課題、主要供應商、市場機會、市場佔有率的因素、波特的五力分析,及主要企業的簡介等彙整。

第1章 摘要整理

第2章 調查範圍

  • 分析概要
  • 主要供應商的產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

第5章 疾病概要

  • 疾病的理解
  • 病理學
  • 病因
  • 徵兆、症狀
  • 診斷
  • 分期
  • 日本的病期分類系統
  • 治療
  • 流行病學
  • 經濟負擔

第6章 開發平台的組合

  • 開發平台候補藥相關資訊

第7章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第8章 市場區隔:各分子類型

  • 小分子
  • 生技藥品

第9章 市場區隔:各給藥途徑

  • 口服
  • 非口服

第10章 市場區隔:化療的各線

  • 一線化療
  • 二線藥物化療

第11章 地區區分

  • 全球胃癌治療藥市場:各區域區隔
  • APAC (亞太地區) 的胃癌治療藥市場
  • 日本的胃癌治療藥市場
  • 中國的胃癌治療藥市場
  • 南北美洲的胃癌治療藥市場
  • EMEA (歐洲、中東、非洲) 的胃癌治療藥市場

第12章 市場成長的推動要素

  • 有前途的開發平台治療藥
  • 醫療的未滿足需求
  • 患者人口的增加
  • 患者援助計劃

第13章 推動因素的影響

第14章 市場課題

  • 高價的治療藥
  • 有害的副作用
  • 治療藥的不足
  • 診斷的延遲

第15章 推動因素、課題的影響

第16章 市場趨勢

  • 社會認識的高漲
  • 非標籤藥物醫藥品的使用
  • 供應商間的競爭激烈

第17章 供應商環境

  • 競爭情形
  • 市場佔有率分析
  • Eli Lilly

第18章 主要供應商分析

  • BASF
  • Bayer CropScience
  • RALLIS
  • Syngenta
  • UPL Limited

第19章 附錄

  • 簡稱集

第20章 關於Technavio

圖表清單

目錄
Product Code: IRTNTR7982

Market outlook of the global gastric cancer drugs market

Technavio's market research analyst predicts the global gastric cancer drugs market to grow rapidly at a CAGR of approximately 8% during the forecast period. The presence of huge unmet needs in the market is expected to result in this market's healthy growth during the forecast period. The presence of this high-unmet medical need will lead to an increased R&D of safe and effective drugs, which in turn will spur market growth during the estimated period.

The recent increase in the prevalence of gastric cancer due to lifestyle changes is expected to drive market growth. The sedentary lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity are envisaged to result in the increased incidence of gastric cancer.

Geographical segmentation and analysis of the gastric cancer drugs market

  • Americas
  • APAC
  • Europe

In this market study, analysts have estimated the APAC region to account for the highest market share during the forecast period. Much of this region's growth can be attributed to the increasing demand for better healthcare infrastructure, which results in its massive market share of nearly 48% during the forecast period.

Competitive landscape and key vendors

The global gastric cancer drugs market is growing rapidly owing to the high proportion of individuals with gastric cancer and the presence of a strong drug pipeline. To gain traction in this market, the vendors are manufacturing and marketing gastric cancer drugs that exhibit a high safety and efficacy profile, this helps the vendors to gain a competitive edge over their peers.

The top vendors in the market are -

  • Hoffmann-La Roche
  • Eli-lilly
  • Sanofi
  • Otsuka Holdings

Other prominent vendors in the market include Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global gastric cancer drugs market?
  • What are the key market trends impacting the growth of the gastric cancer drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the vendors in the global gastric cancer drugs market?
  • Trending factors influencing the market shares of the Americas, APAC, and Europe?
  • What are the key outcomes of the five forces analysis of the gastric cancer drugs market?

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators
<> PART 04: Introduction

PART 05: Disease overview

  • Understanding the disease
  • Pathophysiology
  • Causes
  • Signs and symptoms
  • Diagnosis
  • Staging
  • Japanese staging system
  • Treatment
  • Epidemiology
  • Economic burden

PART 06: Pipeline portfolio

  • Information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by molecule type

  • Small molecules
  • Biologics

PART 09: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 10: Market segmentation by lines of chemotherapy

  • First-line chemotherapy
  • Second-line chemotherapy

PART 11: Geographical segmentation

  • Global gastric cancer drugs market by geographical segmentation 2015-2020
  • Gastric cancer drugs market in APAC
  • Gastric cancer drugs market in Japan
  • Gastric cancer drugs market in China
  • Gastric cancer drugs market in Americas
  • Gastric cancer drugs market in EMEA

PART 12: Market drivers

  • Promising drug pipeline
  • Unmet medical needs
  • Increase in patient population
  • Patient assistance programs

PART 13: Impact of drivers

PART 14: Market challenges

  • High cost of drugs
  • Adverse side effects
  • Shortage of drugs
  • Delayed diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Rise in public awareness
  • Use of off-label drugs
  • Intense competition among vendors

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Eli Lilly

PART 18: Key vendor analysis

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Otsuka Holdings
  • Sanofi
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviation

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings 9
  • Exhibit 02: Types of gastric cancer
  • Exhibit 03: Frequency of different types of gastric cancers
  • Exhibit 04: Causes of gastric cancer
  • Exhibit 05: Signs and symptoms of gastric cancer
  • Exhibit 06: Diagnostic tests for gastric cancer
  • Exhibit 07: Staging of gastric cancer
  • Exhibit 08: Treatment options for gastric cancer
  • Exhibit 09: First-line therapy for metastatic or locally advanced gastric cancer
  • Exhibit 10: Second-line therapy for gastric cancer
  • Exhibit 11: Surgeries for gastric cancer
  • Exhibit 12: Types of radiation therapy for gastric cancer
  • Exhibit 13: Estimated number of new cancers (all ages) males and females in Americas, EMEA, and APAC: 2015 and 2020
  • Exhibit 14: Estimated number of new cancers (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
  • Exhibit 15: Estimated number of mortality cases (all ages) males and females in Americas, EMEA, and APAC: 2015
  • Exhibit 16: Estimated number of mortality cases (age <65 and >=65) males and females in Americas, EMEA, and APAC: 2015
  • Exhibit 17: Pipeline molecules for gastric cancer
  • Exhibit 18: Gastric cancer clinical trials by development phase
  • Exhibit 19: Gastric cancer clinical trials by trial status
  • Exhibit 20: Global gastric cancer drugs market 2015-2020 ($ millions)
  • Exhibit 21: Five forces analysis
  • Exhibit 22: Global gastric cancer drugs market segmented by molecule type
  • Exhibit 23: Global gastric cancer drugs market segmented by route of administration
  • Exhibit 24: Dose and administration schedule of Teysuno (S-1) plus cisplatin
  • Exhibit 25: Lines of therapy for the treatment of advanced gastric cancer
  • Exhibit 26: Estimated annual cost per patient for chemotherapy regimen in EU ($ millions)
  • Exhibit 27: Global gastric cancer drugs market by geographical segmentation 2015
  • Exhibit 28: Global gastric cancer drugs market region wise 2015-2020 ($ millions)
  • Exhibit 29: Gastric cancer drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 30: Gastric cancer drugs market in Japan 2015-2020 ($ millions)
  • Exhibit 31: Gastric cancer drugs market in China 2015-2020 ($ millions)
  • Exhibit 32: Gastric cancer drugs market in Japan and China 2015-2020 ($ millions)
  • Exhibit 33: Gastric cancer drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 34: Gastric cancer drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 35: Key drivers for global gastric cancer drugs market
  • Exhibit 36: Number of patients treated with Herceptin via Patient Assistance Program in China
  • Exhibit 37: Impact of drivers
  • Exhibit 38: Challenges of global gastric cancer drugs market
  • Exhibit 39: Average cost comparison of Herceptin
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Trends of global gastric cancer drugs market
  • Exhibit 42: Timeline of Cyramza in US, EU, and Japan
  • Exhibit 43: Eli Lilly: Key takeaways
  • Exhibit 44: Timeline of Herceptin in US, EU, and Japan
  • Exhibit 45: F. Hoffmann-La Roche: Global YoY growth and revenue of Herceptin 2011-2014 ($ millions)
  • Exhibit 46: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in US 2013-2014 ($ millions)
  • Exhibit 47: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in EU 2013-2014 ($ millions)
  • Exhibit 48: F. Hoffmann-La Roche: YoY growth and revenue of Herceptin in Japan 2013-2014 ($ millions)
  • Exhibit 49: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 50: Timeline of Tegafur in Japan, EU, and Asia
  • Exhibit 51: Otsuka Holdings: Key takeaways
  • Exhibit 52: Timeline of Taxotere in US, EU, and Japan
  • Exhibit 53: Sanofi: Global YoY growth and revenue of Taxotere 2011-2014 ($ millions)
  • Exhibit 54: Sanofi: YoY growth and revenue of Taxotere in US 2011-2014 ($ millions)
  • Exhibit 55: Sanofi: YoY growth and revenue of Taxotere in EU 2011-2014 ($ millions)
  • Exhibit 56: Sanofi: Key takeaways
  • Exhibit 57: Eli Lilly: Business segmentation by revenue 2014
  • Exhibit 58: Eli Lily: Business/Product segmentation by revenue 2012 and 2013 ($ millions)
  • Exhibit 59: Eli Lily: Geographical segmentation by revenue 2014
  • Exhibit 60: F. Hoffmann-La Roche: Business segmentation by revenue 2014
  • Exhibit 61: F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 62: F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
  • Exhibit 63: Otsuka Holdings: Business segmentation 2014 by revenue
  • Exhibit 64: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 65: Otsuka Holdings: Geographical segmentation by revenue 2014
  • Exhibit 66: Sanofi: Business segmentation by revenue 2014
  • Exhibit 67: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 68: Sanofi: Geographical segmentation by revenue 2014
Back to Top